Daily Pharma Scoop 2017-09-25: Gilead at mid-80s , Keytruda new label, Ascendis positive trial

  • A Gilead article is discussed - should it be bought now?
  • Keytruda gets a new label.
  • Ascendis is up on Versartis phase 3 failure in pediatric growth hormone deficiency.

Analysis of top Seeking Alpha coverage

Why We Bought Gilead This Week by RobinhoodStrategy - This is not an Editor’s Pick article, however, this weekend there are no proper Editor’s Picks in healthcare so we will go with this one mainly because I am interested to know why someone would buy Gilead (GILD) now and not when it was below $70. 🙂

The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.

An abridged version is available below to our investor members. Login or Subscribe here.